Bupivacaine + Epinephrine

Generic name: Bupivacaine hydrochloride + Epinephrine / Adrenaline

Category: Long-acting amide local anesthetic + vasoconstrictor

Common brand names: Marcaine with Epinephrine, Vivacaine, Sensorcaine with Epinephrine. Brand availability, cartridge volume, and concentration vary by country.

This article is for dental education only. Bupivacaine with epinephrine is a long-acting dental local anesthetic and should be used only by trained clinicians who understand dose calculation, aspiration technique, intravascular injection risk, prolonged numbness precautions, cardiovascular toxicity, and emergency management of local anesthetic systemic toxicity. It is not the routine choice for every short dental procedure.

Bupivacaine with epinephrine is a long-acting amide local anesthetic used in dentistry when extended anesthesia is clinically useful. It is commonly supplied as 0.5% bupivacaine with epinephrine 1:200,000.

Its main value is prolonged postoperative analgesia after oral surgery, extractions, or painful procedures where a longer anesthetic effect may reduce early postoperative pain.

The main safety concern is that bupivacaine has a higher cardiac toxicity concern than many shorter-acting dental anesthetics, and its long numbness increases the risk of lip, cheek, or tongue biting.

• Best use: selected long-duration dental anesthesia and postoperative pain control
• Common dental context: surgical extraction, periodontal surgery, implant surgery, extensive oral surgery, end-of-procedure long-acting block
• Main advantage: prolonged anesthesia and early postoperative analgesia
• Main limitation: long soft-tissue numbness and higher concern for cardiotoxicity if systemic toxicity occurs
• Clinical priority: use selectively, calculate dose carefully, aspirate, inject slowly, and warn about prolonged numbness

• Long-acting local anesthesia for selected oral surgical procedures
• Postoperative pain reduction after surgical extraction or difficult extraction
• End-of-procedure nerve block to extend analgesia after surgery
• Periodontal surgery when prolonged soft-tissue anesthesia is useful
• Implant surgery or bone-related procedures requiring longer postoperative comfort
• Selected patients where reducing early postoperative rescue analgesic need is helpful
• Not usually necessary for very short, simple restorative procedures

Example only: A common dental formulation is bupivacaine 0.5% with epinephrine 1:200,000. This means 5 mg/mL. One 1.8 mL dental cartridge contains about 9 mg bupivacaine.

For dental use, product information commonly states that the total dose should not ordinarily exceed 90 mg in a healthy adult dental sitting, equivalent to about ten 1.8 mL cartridges of 0.5% bupivacaine with epinephrine.

In real dental care, the practical limit is usually much lower because bupivacaine is selected for targeted long-duration anesthesia, not for routine high-volume repeated injections.

Dose must always consider body weight, age, liver function, cardiovascular status, pregnancy, total local anesthetic exposure, epinephrine exposure, injection site, aspiration result, and whether other local anesthetics were used during the appointment.

• Known hypersensitivity to bupivacaine or other amide local anesthetics
• Known hypersensitivity to sulfites when using epinephrine-containing cartridges that contain sulfite antioxidants
• Use beyond maximum safe dose or without ability to manage toxicity
• Unsafe injection technique or suspected intravascular injection
• Severe conduction disturbance, serious uncontrolled arrhythmia, or significant cardiac instability without medical guidance
• Recent myocardial infarction, unstable angina, or severe uncontrolled hypertension without medical approval
• Severe liver disease or markedly impaired local anesthetic metabolism requiring dose reduction or medical input
• Situations where prolonged numbness is unsafe, poorly tolerated, or difficult for the patient to manage
• Use in small children unless local labeling, dosing, and clinical indication clearly support it

• Local anesthetic systemic toxicity: may occur after overdose, repeated dosing, rapid absorption, or intravascular injection.
• Cardiotoxicity concern: bupivacaine toxicity can be especially dangerous because of serious arrhythmias and cardiovascular collapse.
• Early toxicity signs: metallic taste, circumoral numbness, tongue numbness, tinnitus, dizziness, agitation, confusion, visual disturbance, tremor, or slurred speech.
• Severe toxicity: seizures, reduced consciousness, respiratory depression, ventricular arrhythmia, hypotension, cardiovascular collapse, or cardiac arrest.
• Long numbness: soft-tissue anesthesia may last for hours and increases the risk of biting injury.
• Epinephrine effects: palpitations, tremor, anxiety-like feeling, increased heart rate, increased blood pressure, or headache may occur, especially after intravascular injection.
• Patient selection: bupivacaine should be chosen because long duration is clinically useful, not simply as a default anesthetic.

Bupivacaine is useful when long postoperative analgesia is needed, but it has a narrower comfort zone if systemic toxicity occurs. Avoid rapid injection, always aspirate, avoid repeated unnecessary cartridges, and keep emergency management for local anesthetic systemic toxicity ready.

• Other local anesthetics: total local anesthetic dose is additive and increases toxicity risk.
• Class I antiarrhythmic drugs: may have additive cardiac conduction effects with amide local anesthetics.
• Nonselective beta-blockers: may increase hypertensive response to epinephrine.
• Tricyclic antidepressants: may increase cardiovascular response to epinephrine.
• MAO inhibitors: may increase pressor response risk with sympathomimetic agents.
• Certain antipsychotics: may alter blood pressure response to epinephrine.
• Cocaine or stimulant use: can significantly increase cardiovascular risk when combined with epinephrine.
• Sedatives or general anesthetics: may change monitoring needs and respiratory/cardiovascular safety planning.
• Hepatic impairment or medicines affecting liver metabolism: may increase concern with repeated or high-dose exposure.

• Prolonged numbness of lip, cheek, tongue, or soft tissues
• Injection-site pain, bruising, or hematoma
• Dizziness, lightheadedness, headache, nausea, or drowsiness
• Palpitations, tremor, anxiety-like feeling, or temporary increased heart rate from epinephrine
• Blood pressure changes in susceptible patients
• Post-anesthetic lip, cheek, or tongue biting injury
• Persistent numbness, tingling, or altered sensation requiring follow-up
• Rare allergy or sulfite sensitivity reaction
• Rare but serious: seizure, ventricular arrhythmia, respiratory depression, cardiovascular collapse, cardiac arrest, severe systemic toxicity

• Expect numbness to last longer than with many routine dental anesthetics.
• Do not chew food until the numbness has worn off to avoid biting the lip, cheek, or tongue.
• Children should be supervised very carefully while numb because biting injuries can be severe.
• A temporary racing-heart or shaky feeling can happen after epinephrine, but severe symptoms should be reported immediately.
• Tell the dentist about heart disease, rhythm problems, high blood pressure, liver disease, pregnancy, stimulant use, and all medications.
• Report previous reactions to dental anesthesia, including fainting, palpitations, rash, swelling, breathing difficulty, or persistent numbness.
• Seek urgent help for breathing difficulty, seizure, severe dizziness, chest pain, irregular heartbeat, facial swelling, throat swelling, or collapse.
• Contact the clinic if numbness lasts unusually long, altered sensation persists, swelling worsens, severe pain develops, or infection signs appear.

Bupivacaine is not chosen because it is “stronger” for every case; it is chosen because it lasts longer. The best use is targeted: for example, after a surgical extraction or oral surgery procedure where prolonged postoperative analgesia is useful. The key safety memory is: long duration, low cartridge milligrams, but high toxicity seriousness if injected intravascularly or overdosed.

• Metallic taste, circumoral numbness, tinnitus, visual disturbance, agitation, confusion, tremor, slurred speech, or seizure after injection
• Severe dizziness, fainting, collapse, or altered consciousness
• Irregular heartbeat, chest pain, severe hypotension, severe hypertension symptoms, or cardiovascular collapse
• Difficulty breathing, wheezing, facial swelling, throat swelling, or suspected allergic reaction
• Persistent numbness, tingling, altered sensation, or neurologic symptoms after anesthesia
• Severe lip, cheek, or tongue biting injury while numb
• Uncontrolled bleeding, expanding hematoma, or rapidly increasing swelling
• Any suspected local anesthetic systemic toxicity requiring emergency management

• Lidocaine + Epinephrine
• Articaine + Epinephrine
• Mepivacaine
• Prilocaine
• Epinephrine / Adrenaline
• Felypressin
• Topical lidocaine
• Lipid emulsion therapy for severe local anesthetic systemic toxicity

Bupivacaine with epinephrine is a long-acting dental local anesthetic used mainly when extended anesthesia and postoperative analgesia are useful, such as after oral surgery, surgical extraction, periodontal surgery, or implant-related procedures. It is commonly supplied as 0.5% bupivacaine with epinephrine 1:200,000, and one 1.8 mL cartridge contains about 9 mg. Safe use requires selective indication, careful dose calculation, aspiration, slow injection, awareness of cardiac toxicity, attention to additive local anesthetic dose, and strong patient advice about prolonged numbness and biting injury.